Minneapolis, MNNow Enrolling

Neurofibromatosis Type 2 Clinical Trial in Minneapolis, MN

Access cutting-edge neurofibromatosis type 2 treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Expert Care

Access neurofibromatosis type 2 specialists in Minneapolis at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neurofibromatosis type 2 treatment provided free

About This Neurofibromatosis Type 2 Study in Minneapolis

This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.

Sponsor: Recursion Pharmaceuticals Inc.

Apply for This Minneapolis Location

Check if you qualify for this neurofibromatosis type 2 clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Neurofibromatosis Type 2 Treatment Options in Minneapolis, MN

If you're searching for neurofibromatosis type 2 treatment options in Minneapolis, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neurofibromatosis type 2 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Why Consider a Clinical Trial for Neurofibromatosis Type 2?

  • Access to new treatments before they're widely available
  • Receive care from leading neurofibromatosis type 2 specialists in Minneapolis
  • Contribute to medical research that could help future patients
  • Study-related care is typically provided at no cost
  • Close monitoring by a dedicated research team
  • Possible compensation for time and travel